Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
Adding catheter-directed thrombolysis to standard anticoagulation cuts the risk of death, PE recurrence, and cardiorespiratory collapse by 90% in intermediate-high-risk pulmonary embolism patients, the PRAGUE-26 trial found. Published in the NEJM and presented at ESC Congress 2026, the results could reshape PE treatment guidelines — which haven't meaningfully changed in 30 years.
Pulmonary embolism (PE) kills at rates comparable to heart attacks, yet most patients are still managed the same way they were three decades ago — anticoagulation, and systemic thrombolysis only if things go south. The PRAGUE-26 trial, presented at ESC Congress 2026 and published simultaneously in the New England Journal of Medicine, is making a strong case for change.
The randomized trial enrolled 558 patients with intermediate-high-risk acute PE across 11 Czech centers. Half received standard anticoagulation alone; the other half got catheter-directed thrombolysis with alteplase on top. The results were striking: the thrombolysis group had a 90% lower risk of the composite primary outcome (death, PE recurrence, or cardiorespiratory decompensation/collapse within 7 days). Crucially, bleeding rates — including major bleeding — were similar between groups, and the procedure requires no specialized equipment beyond a standard cath lab.
By the Numbers:
Why it matters: New European PE guidelines are expected in 2027, and investigators are hopeful PRAGUE-26 — alongside HI-PEITHO — will push catheter-directed thrombolysis into first-line recommendations for intermediate-high-risk PE, potentially transforming how care is organized globally.
